Sentence	entity_1	entity_2	entity_3	entity_4	entity_5	entity_6	entity_7	entity_8	entity_9	entity_10	entity_11	entity_12	entity_13	entity_14	json	split
The results of supershift analysis using specific antibodies against transcription factors suggested that both binding complexes contained the NF - kappaB components p50 and p65, and did not contain other NF - kappaB proteins ( p52, c - Rel, Rel B), AP - 1 proteins ( c - Fos, C - Jun), CREB or C / EBPbeta ( NF - IL6).	transcription factors,69,90,Gene/Protein	NF - kappaB components,143,165,Gene/Protein	p50,166,169,Gene/Protein	p65,174,177,Gene/Protein	NF - kappaB proteins,205,225,Gene/Protein	p52,228,231,Gene/Protein	c - Rel,233,240,Gene/Protein	Rel B,242,247,Gene/Protein	AP - 1 proteins,250,265,Gene/Protein	c - Fos,268,275,Gene/Protein	C - Jun,277,284,Gene/Protein	CREB,287,291,Gene/Protein	C / EBPbeta,295,306,Gene/Protein	NF - IL6,309,317,Gene/Protein	"[{""token"": ""transcription factors"", ""start_span"": 69, ""end_span"": 90, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB components"", ""start_span"": 143, ""end_span"": 165, ""type"": ""Gene/Protein""}, {""token"": ""p50"", ""start_span"": 166, ""end_span"": 169, ""type"": ""Gene/Protein""}, {""token"": ""p65"", ""start_span"": 174, ""end_span"": 177, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB proteins"", ""start_span"": 205, ""end_span"": 225, ""type"": ""Gene/Protein""}, {""token"": ""p52"", ""start_span"": 228, ""end_span"": 231, ""type"": ""Gene/Protein""}, {""token"": ""c - Rel"", ""start_span"": 233, ""end_span"": 240, ""type"": ""Gene/Protein""}, {""token"": ""Rel B"", ""start_span"": 242, ""end_span"": 247, ""type"": ""Gene/Protein""}, {""token"": ""AP - 1 proteins"", ""start_span"": 250, ""end_span"": 265, ""type"": ""Gene/Protein""}, {""token"": ""c - Fos"", ""start_span"": 268, ""end_span"": 275, ""type"": ""Gene/Protein""}, {""token"": ""C - Jun"", ""start_span"": 277, ""end_span"": 284, ""type"": ""Gene/Protein""}, {""token"": ""CREB"", ""start_span"": 287, ""end_span"": 291, ""type"": ""Gene/Protein""}, {""token"": ""C / EBPbeta"", ""start_span"": 295, ""end_span"": 306, ""type"": ""Gene/Protein""}, {""token"": ""NF - IL6"", ""start_span"": 309, ""end_span"": 317, ""type"": ""Gene/Protein""}]"	train
We demonstrate that: 1) RANTES promoter activity is up - regulated by PMA plus ionomycin, coexpression of the p65 subunit of nuclear factor ( NF) - kappa B, the proinflammatory cytokines TNF - alpha and IL - 1 beta, and the CD28 costimulatory pathway; 2) the RANTES promoter region contains four NF - kappa B binding sites at positions - 30, - 44, - 213, and - 579 relative to the transcription start site; 3) one site ( - 213) is an NF - AT ( nuclear factor of activated T cells) binding site that also has weak affinity to NF - kappa B, and the most distal site ( - 579) also serves as a CD28 - responsive element; and 4) mutation on any of those NF - kappa B sites or coexpression of I kappa B alpha ( cytoplasmic inhibitor of NF - kappa B) markedly reduced the promoter activity.	RANTES,24,30,Gene/Protein	p65 subunit,110,121,Gene/Protein	proinflammatory cytokines,161,186,Gene/Protein	TNF - alpha,187,198,Gene/Protein	IL - 1 beta,203,214,Gene/Protein	CD28,224,228,Gene/Protein	RANTES promoter region,259,281,Gene/Protein	NF - kappa B binding sites,296,322,Gene/Protein	transcription start site,381,405,Gene/Protein	NF - kappa B,525,537,Gene/Protein	CD28 - responsive element,590,615,Gene/Protein	NF - kappa B sites,649,667,Gene/Protein	I kappa B alpha,687,702,Gene/Protein	cytoplasmic inhibitor of NF - kappa B,705,742,Gene/Protein	"[{""token"": ""RANTES"", ""start_span"": 24, ""end_span"": 30, ""type"": ""Gene/Protein""}, {""token"": ""p65 subunit"", ""start_span"": 110, ""end_span"": 121, ""type"": ""Gene/Protein""}, {""token"": ""proinflammatory cytokines"", ""start_span"": 161, ""end_span"": 186, ""type"": ""Gene/Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 187, ""end_span"": 198, ""type"": ""Gene/Protein""}, {""token"": ""IL - 1 beta"", ""start_span"": 203, ""end_span"": 214, ""type"": ""Gene/Protein""}, {""token"": ""CD28"", ""start_span"": 224, ""end_span"": 228, ""type"": ""Gene/Protein""}, {""token"": ""RANTES promoter region"", ""start_span"": 259, ""end_span"": 281, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B binding sites"", ""start_span"": 296, ""end_span"": 322, ""type"": ""Gene/Protein""}, {""token"": ""transcription start site"", ""start_span"": 381, ""end_span"": 405, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B"", ""start_span"": 525, ""end_span"": 537, ""type"": ""Gene/Protein""}, {""token"": ""CD28 - responsive element"", ""start_span"": 590, ""end_span"": 615, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B sites"", ""start_span"": 649, ""end_span"": 667, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B alpha"", ""start_span"": 687, ""end_span"": 702, ""type"": ""Gene/Protein""}, {""token"": ""cytoplasmic inhibitor of NF - kappa B"", ""start_span"": 705, ""end_span"": 742, ""type"": ""Gene/Protein""}]"	train
Results from in vivo expression studies performed with these NF - kappa B p65 mutants revealed the following: 1) I kappa B / MAD - 3 completely inhibits NF - kappa B p65 - dependent transcriptional activation mediated through the human immunodeficiency virus type 1 kappa B enhancer in human T lymphocytes, 2) the binding of I kappa B / MAD - 3 to NF - kappa B p65 is sufficient to retarget NF - kappa B p65 from the nucleus to the cytoplasm, 3) selective deletion of the functional nuclear localization signal present in the Rel homology domain of NF - kappa B p65 disrupts its ability to engage I kappa B / MAD - 3, and 4) the unique C - terminus of NF - kappa B p65 attenuates its own nuclear localization and contains sequences that are required for I kappa B - mediated inhibition of NF - kappa B p65 DNA binding activity.	NF - kappa B p65 mutants,61,85,Gene/Protein	I kappa B / MAD - 3,113,132,Gene/Protein	NF - kappa B p65,153,169,Gene/Protein	human immunodeficiency virus type 1 kappa B enhancer,230,282,Gene/Protein	I kappa B / MAD - 3,325,344,Gene/Protein	NF - kappa B p65,348,364,Gene/Protein	NF - kappa B p65,391,407,Gene/Protein	Rel homology domain,526,545,Gene/Protein	NF - kappa B p65,549,565,Gene/Protein	I kappa B / MAD - 3,597,616,Gene/Protein	C - terminus,636,648,Gene/Protein	NF - kappa B p65,652,668,Gene/Protein	I kappa B,754,763,Gene/Protein	NF - kappa B p65,789,805,Gene/Protein	"[{""token"": ""NF - kappa B p65 mutants"", ""start_span"": 61, ""end_span"": 85, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B / MAD - 3"", ""start_span"": 113, ""end_span"": 132, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 153, ""end_span"": 169, ""type"": ""Gene/Protein""}, {""token"": ""human immunodeficiency virus type 1 kappa B enhancer"", ""start_span"": 230, ""end_span"": 282, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B / MAD - 3"", ""start_span"": 325, ""end_span"": 344, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 348, ""end_span"": 364, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 391, ""end_span"": 407, ""type"": ""Gene/Protein""}, {""token"": ""Rel homology domain"", ""start_span"": 526, ""end_span"": 545, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 549, ""end_span"": 565, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B / MAD - 3"", ""start_span"": 597, ""end_span"": 616, ""type"": ""Gene/Protein""}, {""token"": ""C - terminus"", ""start_span"": 636, ""end_span"": 648, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 652, ""end_span"": 668, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B"", ""start_span"": 754, ""end_span"": 763, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 789, ""end_span"": 805, ""type"": ""Gene/Protein""}]"	train
NF - kappaB activation by LMP1 ( 1 - 231) is likely to be mediated by TRAF1 / TRAF2 heteroaggregates since TRAF1 is unique among the TRAFs in coactivating NF - kappaB with LMP1 ( 1 - 231), a TRAF2 dominant - negative mutant can block LMP1 ( 1 - 231) - mediated NF - kappaB activation as well as TRAF1 coactivation, and 30% of TRAF2 is associated with TRAF1 in EBV - transformed B cells.	NF - kappaB,0,11,Gene/Protein	LMP1,26,30,Gene/Protein	TRAF1,70,75,Gene/Protein	/ TRAF2,76,83,Gene/Protein	TRAF1,107,112,Gene/Protein	TRAFs,133,138,Gene/Protein	NF - kappaB,155,166,Gene/Protein	LMP1,172,176,Gene/Protein	TRAF2,191,196,Gene/Protein	LMP1,234,238,Gene/Protein	NF - kappaB,261,272,Gene/Protein	TRAF1,295,300,Gene/Protein	TRAF2,326,331,Gene/Protein	TRAF1,351,356,Gene/Protein	"[{""token"": ""NF - kappaB"", ""start_span"": 0, ""end_span"": 11, ""type"": ""Gene/Protein""}, {""token"": ""LMP1"", ""start_span"": 26, ""end_span"": 30, ""type"": ""Gene/Protein""}, {""token"": ""TRAF1"", ""start_span"": 70, ""end_span"": 75, ""type"": ""Gene/Protein""}, {""token"": ""/ TRAF2"", ""start_span"": 76, ""end_span"": 83, ""type"": ""Gene/Protein""}, {""token"": ""TRAF1"", ""start_span"": 107, ""end_span"": 112, ""type"": ""Gene/Protein""}, {""token"": ""TRAFs"", ""start_span"": 133, ""end_span"": 138, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB"", ""start_span"": 155, ""end_span"": 166, ""type"": ""Gene/Protein""}, {""token"": ""LMP1"", ""start_span"": 172, ""end_span"": 176, ""type"": ""Gene/Protein""}, {""token"": ""TRAF2"", ""start_span"": 191, ""end_span"": 196, ""type"": ""Gene/Protein""}, {""token"": ""LMP1"", ""start_span"": 234, ""end_span"": 238, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB"", ""start_span"": 261, ""end_span"": 272, ""type"": ""Gene/Protein""}, {""token"": ""TRAF1"", ""start_span"": 295, ""end_span"": 300, ""type"": ""Gene/Protein""}, {""token"": ""TRAF2"", ""start_span"": 326, ""end_span"": 331, ""type"": ""Gene/Protein""}, {""token"": ""TRAF1"", ""start_span"": 351, ""end_span"": 356, ""type"": ""Gene/Protein""}]"	valid
The results of supershift analysis using specific antibodies against transcription factors suggested that both binding complexes contained the NF - kappaB components p50 and p65, and did not contain other NF - kappaB proteins ( p52, c - Rel, Rel B), AP - 1 proteins ( c - Fos, C - Jun), CREB or C / EBPbeta ( NF - IL6).	transcription factors,69,90,Gene/Protein	NF - kappaB components,143,165,Gene/Protein	p50,166,169,Gene/Protein	p65,174,177,Gene/Protein	NF - kappaB proteins,205,225,Gene/Protein	p52,228,231,Gene/Protein	c - Rel,233,240,Gene/Protein	Rel B,242,247,Gene/Protein	AP - 1 proteins,250,265,Gene/Protein	c - Fos,268,275,Gene/Protein	C - Jun,277,284,Gene/Protein	CREB,287,291,Gene/Protein	C / EBPbeta,295,306,Gene/Protein	NF - IL6,309,317,Gene/Protein	"[{""token"": ""transcription factors"", ""start_span"": 69, ""end_span"": 90, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB components"", ""start_span"": 143, ""end_span"": 165, ""type"": ""Gene/Protein""}, {""token"": ""p50"", ""start_span"": 166, ""end_span"": 169, ""type"": ""Gene/Protein""}, {""token"": ""p65"", ""start_span"": 174, ""end_span"": 177, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB proteins"", ""start_span"": 205, ""end_span"": 225, ""type"": ""Gene/Protein""}, {""token"": ""p52"", ""start_span"": 228, ""end_span"": 231, ""type"": ""Gene/Protein""}, {""token"": ""c - Rel"", ""start_span"": 233, ""end_span"": 240, ""type"": ""Gene/Protein""}, {""token"": ""Rel B"", ""start_span"": 242, ""end_span"": 247, ""type"": ""Gene/Protein""}, {""token"": ""AP - 1 proteins"", ""start_span"": 250, ""end_span"": 265, ""type"": ""Gene/Protein""}, {""token"": ""c - Fos"", ""start_span"": 268, ""end_span"": 275, ""type"": ""Gene/Protein""}, {""token"": ""C - Jun"", ""start_span"": 277, ""end_span"": 284, ""type"": ""Gene/Protein""}, {""token"": ""CREB"", ""start_span"": 287, ""end_span"": 291, ""type"": ""Gene/Protein""}, {""token"": ""C / EBPbeta"", ""start_span"": 295, ""end_span"": 306, ""type"": ""Gene/Protein""}, {""token"": ""NF - IL6"", ""start_span"": 309, ""end_span"": 317, ""type"": ""Gene/Protein""}]"	train
We demonstrate that: 1) RANTES promoter activity is up - regulated by PMA plus ionomycin, coexpression of the p65 subunit of nuclear factor ( NF) - kappa B, the proinflammatory cytokines TNF - alpha and IL - 1 beta, and the CD28 costimulatory pathway; 2) the RANTES promoter region contains four NF - kappa B binding sites at positions - 30, - 44, - 213, and - 579 relative to the transcription start site; 3) one site ( - 213) is an NF - AT ( nuclear factor of activated T cells) binding site that also has weak affinity to NF - kappa B, and the most distal site ( - 579) also serves as a CD28 - responsive element; and 4) mutation on any of those NF - kappa B sites or coexpression of I kappa B alpha ( cytoplasmic inhibitor of NF - kappa B) markedly reduced the promoter activity.	RANTES,24,30,Gene/Protein	p65 subunit,110,121,Gene/Protein	proinflammatory cytokines,161,186,Gene/Protein	TNF - alpha,187,198,Gene/Protein	IL - 1 beta,203,214,Gene/Protein	CD28,224,228,Gene/Protein	RANTES promoter region,259,281,Gene/Protein	NF - kappa B binding sites,296,322,Gene/Protein	transcription start site,381,405,Gene/Protein	NF - kappa B,525,537,Gene/Protein	CD28 - responsive element,590,615,Gene/Protein	NF - kappa B sites,649,667,Gene/Protein	I kappa B alpha,687,702,Gene/Protein	cytoplasmic inhibitor of NF - kappa B,705,742,Gene/Protein	"[{""token"": ""RANTES"", ""start_span"": 24, ""end_span"": 30, ""type"": ""Gene/Protein""}, {""token"": ""p65 subunit"", ""start_span"": 110, ""end_span"": 121, ""type"": ""Gene/Protein""}, {""token"": ""proinflammatory cytokines"", ""start_span"": 161, ""end_span"": 186, ""type"": ""Gene/Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 187, ""end_span"": 198, ""type"": ""Gene/Protein""}, {""token"": ""IL - 1 beta"", ""start_span"": 203, ""end_span"": 214, ""type"": ""Gene/Protein""}, {""token"": ""CD28"", ""start_span"": 224, ""end_span"": 228, ""type"": ""Gene/Protein""}, {""token"": ""RANTES promoter region"", ""start_span"": 259, ""end_span"": 281, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B binding sites"", ""start_span"": 296, ""end_span"": 322, ""type"": ""Gene/Protein""}, {""token"": ""transcription start site"", ""start_span"": 381, ""end_span"": 405, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B"", ""start_span"": 525, ""end_span"": 537, ""type"": ""Gene/Protein""}, {""token"": ""CD28 - responsive element"", ""start_span"": 590, ""end_span"": 615, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B sites"", ""start_span"": 649, ""end_span"": 667, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B alpha"", ""start_span"": 687, ""end_span"": 702, ""type"": ""Gene/Protein""}, {""token"": ""cytoplasmic inhibitor of NF - kappa B"", ""start_span"": 705, ""end_span"": 742, ""type"": ""Gene/Protein""}]"	train
Results from in vivo expression studies performed with these NF - kappa B p65 mutants revealed the following: 1) I kappa B / MAD - 3 completely inhibits NF - kappa B p65 - dependent transcriptional activation mediated through the human immunodeficiency virus type 1 kappa B enhancer in human T lymphocytes, 2) the binding of I kappa B / MAD - 3 to NF - kappa B p65 is sufficient to retarget NF - kappa B p65 from the nucleus to the cytoplasm, 3) selective deletion of the functional nuclear localization signal present in the Rel homology domain of NF - kappa B p65 disrupts its ability to engage I kappa B / MAD - 3, and 4) the unique C - terminus of NF - kappa B p65 attenuates its own nuclear localization and contains sequences that are required for I kappa B - mediated inhibition of NF - kappa B p65 DNA binding activity.	NF - kappa B p65 mutants,61,85,Gene/Protein	I kappa B / MAD - 3,113,132,Gene/Protein	NF - kappa B p65,153,169,Gene/Protein	human immunodeficiency virus type 1 kappa B enhancer,230,282,Gene/Protein	I kappa B / MAD - 3,325,344,Gene/Protein	NF - kappa B p65,348,364,Gene/Protein	NF - kappa B p65,391,407,Gene/Protein	Rel homology domain,526,545,Gene/Protein	NF - kappa B p65,549,565,Gene/Protein	I kappa B / MAD - 3,597,616,Gene/Protein	C - terminus,636,648,Gene/Protein	NF - kappa B p65,652,668,Gene/Protein	I kappa B,754,763,Gene/Protein	NF - kappa B p65,789,805,Gene/Protein	"[{""token"": ""NF - kappa B p65 mutants"", ""start_span"": 61, ""end_span"": 85, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B / MAD - 3"", ""start_span"": 113, ""end_span"": 132, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 153, ""end_span"": 169, ""type"": ""Gene/Protein""}, {""token"": ""human immunodeficiency virus type 1 kappa B enhancer"", ""start_span"": 230, ""end_span"": 282, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B / MAD - 3"", ""start_span"": 325, ""end_span"": 344, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 348, ""end_span"": 364, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 391, ""end_span"": 407, ""type"": ""Gene/Protein""}, {""token"": ""Rel homology domain"", ""start_span"": 526, ""end_span"": 545, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 549, ""end_span"": 565, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B / MAD - 3"", ""start_span"": 597, ""end_span"": 616, ""type"": ""Gene/Protein""}, {""token"": ""C - terminus"", ""start_span"": 636, ""end_span"": 648, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 652, ""end_span"": 668, ""type"": ""Gene/Protein""}, {""token"": ""I kappa B"", ""start_span"": 754, ""end_span"": 763, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappa B p65"", ""start_span"": 789, ""end_span"": 805, ""type"": ""Gene/Protein""}]"	train
NF - kappaB activation by LMP1 ( 1 - 231) is likely to be mediated by TRAF1 / TRAF2 heteroaggregates since TRAF1 is unique among the TRAFs in coactivating NF - kappaB with LMP1 ( 1 - 231), a TRAF2 dominant - negative mutant can block LMP1 ( 1 - 231) - mediated NF - kappaB activation as well as TRAF1 coactivation, and 30% of TRAF2 is associated with TRAF1 in EBV - transformed B cells.	NF - kappaB,0,11,Gene/Protein	LMP1,26,30,Gene/Protein	TRAF1,70,75,Gene/Protein	/ TRAF2,76,83,Gene/Protein	TRAF1,107,112,Gene/Protein	TRAFs,133,138,Gene/Protein	NF - kappaB,155,166,Gene/Protein	LMP1,172,176,Gene/Protein	TRAF2,191,196,Gene/Protein	LMP1,234,238,Gene/Protein	NF - kappaB,261,272,Gene/Protein	TRAF1,295,300,Gene/Protein	TRAF2,326,331,Gene/Protein	TRAF1,351,356,Gene/Protein	"[{""token"": ""NF - kappaB"", ""start_span"": 0, ""end_span"": 11, ""type"": ""Gene/Protein""}, {""token"": ""LMP1"", ""start_span"": 26, ""end_span"": 30, ""type"": ""Gene/Protein""}, {""token"": ""TRAF1"", ""start_span"": 70, ""end_span"": 75, ""type"": ""Gene/Protein""}, {""token"": ""/ TRAF2"", ""start_span"": 76, ""end_span"": 83, ""type"": ""Gene/Protein""}, {""token"": ""TRAF1"", ""start_span"": 107, ""end_span"": 112, ""type"": ""Gene/Protein""}, {""token"": ""TRAFs"", ""start_span"": 133, ""end_span"": 138, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB"", ""start_span"": 155, ""end_span"": 166, ""type"": ""Gene/Protein""}, {""token"": ""LMP1"", ""start_span"": 172, ""end_span"": 176, ""type"": ""Gene/Protein""}, {""token"": ""TRAF2"", ""start_span"": 191, ""end_span"": 196, ""type"": ""Gene/Protein""}, {""token"": ""LMP1"", ""start_span"": 234, ""end_span"": 238, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB"", ""start_span"": 261, ""end_span"": 272, ""type"": ""Gene/Protein""}, {""token"": ""TRAF1"", ""start_span"": 295, ""end_span"": 300, ""type"": ""Gene/Protein""}, {""token"": ""TRAF2"", ""start_span"": 326, ""end_span"": 331, ""type"": ""Gene/Protein""}, {""token"": ""TRAF1"", ""start_span"": 351, ""end_span"": 356, ""type"": ""Gene/Protein""}]"	train
